Drug Information
Drug (ID: DG01568) and It's Reported Resistant Information
Name |
TAK-441
|
||||
---|---|---|---|---|---|
Synonyms |
TAK-441; 1186231-83-3; UNII-CY3QT94KWP; CY3QT94KWP; CHEMBL2205230; 6-ethyl-N-[1-(2-hydroxyacetyl)piperidin-4-yl]-1-methyl-4-oxo-5-phenacyl-3-(2,2,2-trifluoroethoxy)pyrrolo[3,2-c]pyridine-2-carboxamide; TAK 441; GTPL8200; SCHEMBL1061476; BCP20946; BDBM50401323; NSC771858; ZINC43207688; NSC-771858; SB18887; LM2094; TAK441; TAK 441; Q27088929; 6-ethyl-N-(1-(2-hydroxyacetyl)piperidin-4-yl)-1-methyl-4-oxo-5-(2-oxo-2-phenylethyl)-3-(2,2,2-trifluoroethoxy)-4,5-dihydro-1H-pyrrolo[3,2-c]pyridine-2-carboxamide
Click to Show/Hide
|
||||
Indication |
In total 1 Indication(s)
|
||||
Structure | |||||
Target | MAPK/ERK kinase kinase (MAP3K) | NOUNIPROTAC | [1] | ||
Click to Show/Hide the Molecular Information and External Link(s) of This Drug | |||||
Formula |
9
|
||||
IsoSMILES |
CCC1=CC2=C(C(=C(N2C)C(=O)NC3CCN(CC3)C(=O)CO)OCC(F)(F)F)C(=O)N1CC(=O)C4=CC=CC=C4
|
||||
InChI |
InChI=1S/C28H31F3N4O6/c1-3-19-13-20-23(27(40)35(19)14-21(37)17-7-5-4-6-8-17)25(41-16-28(29,30)31)24(33(20)2)26(39)32-18-9-11-34(12-10-18)22(38)15-36/h4-8,13,18,36H,3,9-12,14-16H2,1-2H3,(H,32,39)
|
||||
InChIKey |
ZADWXQMNNVICKB-UHFFFAOYSA-N
|
||||
PubChem CID | |||||
TTD Drug ID |
Type(s) of Resistant Mechanism of This Drug
UAPP: Unusual Activation of Pro-survival Pathway
Drug Resistance Data Categorized by Their Corresponding Diseases
ICD-02: Benign/in-situ/malignant neoplasm
Solid tumour/cancer [ICD-11: 2A00-2F9Z]
Drug Sensitivity Data Categorized by Their Corresponding Mechanisms | ||||
Unusual Activation of Pro-survival Pathway (UAPP) | ||||
Key Molecule: Smoothened homolog (SMO) | [1] | |||
Molecule Alteration | Missense mutation | p.D473H (c.1417G>C) |
||
Sensitive Disease | Solid tumour/cancer [ICD-11: 2A00-2F9Z] | |||
Experimental Note | Identified from the Human Clinical Data | |||
In Vitro Model | HEK293T cells | Kidney | Homo sapiens (Human) | CVCL_0063 |
NIH3T3 cells | Embryo | Homo sapiens (Human) | N.A. | |
Experiment for Molecule Alteration |
Western blotting analysis | |||
Experiment for Drug Resistance |
[3H]-TAK-441 radioligand membrane binding assay; Affinity selection-MS binding assay |
References
If you find any error in data or bug in web service, please kindly report it to Dr. Sun and Dr. Zhang.